AINEWS
A Chinese patient is now the first person to legally own a coin sized brain implant, cleared for sale in March by China's regulator, while the U.S. FDA has approved nothing comparable.
A Chinese man who lost the use of his right hand a decade ago has become the first person in the world to legally own an invasive brain-computer interface, a device that reads electrical signals from the brain and turns them into movement or text. The implant, called NEO and made by the Chinese neurotechnology firm Neuracle (also known as Borui Kang Medical Technology), is roughly the size of a coin. It contains eight electrodes. It sits on the surface of the brain's sensorimotor cortex, the strip of tissue that controls voluntary movement, and feeds electrical activity into a decoder that drives a robotic glove on the patient's hand. Sixth Tone's reporting describes a patient who had spent years in rehabilitation before the procedure.
NEO was cleared in March by China's National Medical Products Administration (NMPA), the country's drug-and-device regulator. That decision makes it the first invasive BCI any national regulator has approved for commercial sale. The patient owns the device. He is not a trial subject, and the surgery is not an experiment. It is a medical procedure, billed to a paying customer, performed under a regulatory license to operate.
That distinction is the load-bearing one. A brain implant is no longer hypothetical anywhere. Neuralink, Elon Musk's U.S. brain-implant company, has had electrodes inside human brains since 2024 and had enrolled 21 people in clinical trials this year. But a clinical-trial participant does not own the device, does not pay for it, and cannot be described as a customer. The U.S. Food and Drug Administration has not cleared an invasive BCI for sale. Neither has Europe's MDR system or Japan's PMDA. Until one of them does, China is the only country where a patient can legally leave a hospital with a coin-sized computer in his head.
The mechanism is not a leap. NEO belongs to a class of implants that record electrical activity from small clusters of neurons and feed those signals into a machine-learning system trained to recognize what a patient is trying to do. The patient learns to produce a reliable signal by imagining the motion. The decoder learns what that signal means. Over weeks, the two converge on a workable vocabulary: open the hand, close the hand, lift the cup. The robotic glove is the actuator. The implant is the input device.
The same broad category, BCI, includes non-invasive approaches. Meta's Brain2Qwerty project reads brain activity through scalp sensors and decodes it into text with a large language model. Chinese firm BrainCo sells a bionic prosthetic hand that runs on surface electromyography, the electrical noise left on the skin when a user attempts a motion. Those systems avoid surgery and so carry lower immediate risk, but they read a noisier signal and so far deliver lower fidelity.
The Chinese case is invasive on purpose. The patient lost hand mobility ten years ago after a spinal cord injury. The muscles downstream of the injury no longer fire, so there is no useful surface signal to read. An implant on the brain itself bypasses the broken circuit. The trade-off is surgical risk: opening the skull, threading electrodes onto the cortex, and leaving a foreign object in contact with neural tissue for years. Independent neurosurgical assessment of the NEO procedure and the patient's early post-operative course has not been published in the English-language medical literature, and Chinese state-media coverage of the milestone is the principal source for the surgical team's claims. A peer-reviewed case report is the missing receipt.
The NMPA's March decision, analyzed by the law firm Two Birds, is the structural fact. Once a regulator clears an invasive BCI for sale, hospitals can bill for the procedure, insurers can be asked to cover it, and other manufacturers face a competitor with a real revenue line. Every other national regulator now has a comparator decision to match, qualify, or reject. China's bet is that an aging population and a large spinal-cord-injury caseload will pay for a device that returns a hand.
The falsifier is dated. If Japan's PMDA, Europe's notified bodies, or the U.S. FDA clears any invasive BCI for sale before the end of 2026, the "first commercial" claim collapses. Until then, the world's only legal market for an invasive brain implant is in China, and a man who could not move his right hand for ten years moved it this month.